<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616551</url>
  </required_header>
  <id_info>
    <org_study_id>C2L-OCT-01 PR-301</org_study_id>
    <nct_id>NCT00616551</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients</brief_title>
  <official_title>Open Label, Randomized Study Comparing the Biological Efficacy &amp; Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambrilia Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ambrilia Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the biological safety and efficacy of using the drug,
      C2L-OCT-01 PR, 30 mg to treat acromegalic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the mean serum concentrations of insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in patients treated with C2L-OCT-01 PR, 30 mg or Sandostatin LAR 30 mg</measure>
    <time_frame>Days 1, 28, 42, 56 and 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare plasma concentrations, efficacy and safety profile of C2L-OCT-01 PR</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C2L-OCT-01 PR, 30 mg</intervention_name>
    <description>Administered by deep IM injection (gluteus) on days 1 and 42</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide acetate prolonged release, 30 mg</intervention_name>
    <description>Administered by deep IM (gluteus) on Days 1, 28 and 56</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Sandostatin LAR, 30 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be diagnosed with active acromegaly.

          -  If subject is treated with a long acting somatostatin analogue, the treatment must
             have been unchanged for a period of at least 12 weeks prior to entry.

          -  If subject is treated with a 30 mg dose of a depot formulation of a somatostatin
             analogue, the IGF-1 levels must be normal at entry.

          -  If subject is treated with a 20 mg dose of a depot formulation of a somatostatin
             analogue, any value of IGF-1 is acceptable.

          -  If the subject is receiving an immediate release formulation of a somatostatin
             analogue or a dopamine agonist, the IGF-1 values must be above 10% of the reference
             range based on gender and age.

          -  If the subject is receiving a dopamine agonist, it must be stopped 14 days prior to
             receiving the study medication.

          -  The subject should be able to understand the instructions, provide a written consent
             and abide by the study restrictions.

        Exclusion Criteria:

          -  Women of childbearing potential who are not taking adequate contraception or who are
             pregnant or lactating.

          -  Subjects previously treated with a growth hormone receptor antagonist (Pegvisomant)
             within 12 weeks of study entry.

          -  Subjects who have undergone pituitary surgery within 6 months or radiotherapy within 2
             years prior to admission into the study

          -  Subjects who present some form of intolerance or allergy to the test article or one of
             its non-active ingredients

          -  Subject who have any other condition that alters the growth hormone or IGF-1 levels.

          -  Subjects with signs or symptoms related to a tumor compression of the optical chiasm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Naudin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ambrilia Biopharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Centre for Medical Rehabilitation and Water-therapy</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Általános Orvostudományi</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology &quot;C. I. Parhon&quot; Bucharest</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology, University Clinical Center</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná Nemocnica s Poliklinkou Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>October 7, 2008</last_update_submitted>
  <last_update_submitted_qc>October 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Bonabes de Rouge, M.D./Senior Executive Vice-President &amp; Chief Scientist Officer</name_title>
    <organization>Ambrilia Biopharma, Inc.</organization>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

